March 2024—Like identifying the shift in battle that leads to victory, or the battle that wins the war—let alone declaring a war’s ultimate victor—it’s hard to gauge the whens, ifs, and hows that mark progress in medicine. For those who are deeply rooted in bringing advances to testing in urothelial cancers, current research is flourishing and flummoxing. In early and late stage, both for bladder and upper tract disease, recently approved therapies are leading to better outcomes for patients. More immunotherapies and antibody-drug conjugates are on their way, and with them come new options for testing. But as with any cancer, researchers follow numerous promising paths, knowing that some will dead-end and others will succeed primarily (albeit usefully) in raising more questions. Nevertheless, they continue to rally the work forward, with multiple breaches, and Agincourt, ever in sight. For experts such as David McConkey, PhD, progress will best be measured by how regularly precision makes its way into the clinical setting.
Read More »MARCH 2024
-
Game’s afoot in bladder cancer research
-
From training to first jobs, can the transition be made easier?
March 2024—Pathology trainees and training programs vary, as do first jobs, but the first year in pathology practice is generally said to be a tough one, largely because of the transition to fully independent case sign-out.
-
In diabetes patients, biomarker use for early-stage HF
March 2024—For patients with type 2 diabetes, the cardiac biomarkers are a better predictor of early-stage heart failure than conventional risk prediction scores. “We need to use biomarkers,” says Petr Jarolim, MD, PhD.
-
Survey probes staff shortage in genomics labs
March 2024—From a technologist workforce perspective, clinical genomics laboratories are in trouble. “It’s truly a crisis,” said Marco Leung, PhD, clinical director of the Steve and Cindy Rasmussen Institute for Genomic Medicine at Nationwide Children’s Hospital in Columbus, Ohio.
Image Credits: [do_widget id=enhancedtextwidget-12].
Video Spotlight
-
Epredia Announces Launch of SlideMate Laser
SlideMate Laser is the latest addition to Epredia’s world-class portfolio of precision cancer diagnostics products and services that provide a seamless end-to-end laboratory workflow. SlideMate Laser can integrate into a range a workflows.
Learn more. Read More »
CAP TODAY Roundtables
-
AP and CP reporting, from interfaces to IT wishes
March 2024—Anatomic and clinical pathology reporting—what’s working, what’s missing. Three pathologists (all board certified in informatics) and representatives of three information system companies met online Dec. 19 with CAP TODAY publisher Bob McGonnagle to talk about reporting needs and what’s optimal. The first half of their discussion was published in the February issue, with CAP TODAY’s guide to anatomic pathology computer systems. The second half begins here.
Read More » -
With pipeline for pathologists, others lacking, eyes on AI
-
AP and CP reporting—the needs, the caveats
-
Panelists on viscoelastic and other coag assays
CAP TODAY WEBINARS
-
Combining Clinical Signs and Symptoms with Histopathology for Definitive Diagnosis of Idiopathic Multicentric Castleman Disease (iMCD)
Webinar presenter Jade Neff, MD, PhD, Assistant Professor of Pathology, Duke University Medical Center, discusses Definitive Diagnosis of Idiopathic Multicentric Castleman Disease (iMCD), including the pivotal role that pathologists play in diagnosing iMCD, an elusive and debilitating disease that poses unique diagnostic challenges. Read More » -
Empowering Pathology Partnerships
for Growth & Rewards with GoPathWebinar presenters Jim Lu, MD, PhD, CEO, Medical Director GoPath Diagnostics, and Kenneth Bloom, MD, Head of Pathology, Nucleai, discuss the future of partnerships between community-based pathology groups and (national) laboratories, including sub-specialty coverage, workload balancing, solutions in high-tech diagnostics, turnkey support for digital path and AI, and opportunities for more revenue and higher profits.
Image Credits: [do_widget id=enhancedtextwidget-12].
REGISTER NOW
-
Register for our upcoming webinar
Liquid Biopsy and Concurrent Testing Strategies for Patients with Metastatic NSCLC
Read More »
Thursday, April 11, 2024, 12:00 PM–1:00 PM ET
Webinar presenter Zin Htway, PhD Supervisor and Operations Manager, Anatomic Pathology as HCA, Los Robles Hospital and Medical Center, will discuss the impact of liquid biopsy and concurrent biomarker testing for the appropriate care of patients with NSCLC. Dr. Htway will review the potential benefits of integrating liquid biopsy with standard-of-care tissue testing on turnaround time and identification of patients with actionable biomarkers in metastatic NSCLC and explore patient case scenarios that demonstrate potential successes and implementation considerations for concurrent liquid biopsy integration in metastatic NSCLC. -
Register for our upcoming webinar
Virtual Roundtable: Optimizing Testing for the Diagnosis of Systemic Mastocytosis
June 25, 2024, 1:00 PM–2:00 PM ET
Webinar presenters Robyn Scherber, MD, MPH Hematologist UT Health SA, Medical Director Blueprint Medicines; Anton Rets, MD, PhD Associate Professor University of Utah, Medical Director Hematopathology and Immunohistochemistry; Nathan A. Boggs, MD, PhD Assistant Professor of Medicine, Uniformed Services University Allergy Division Director will discuss the barriers and possible solutions to screening for and diagnosing Systemic Mastocytosis (SM) and recommendations that will empower cross-functional laboratory stakeholders to implement changes that can help improve the diagnosis of SM.
Image Credits: [do_widget id=enhancedtextwidget-12].
AMP Case Reports
-
AMP case report: Acute myeloid leukemia with hyperdiploidy
March 2024—CAP TODAY and the Association for Molecular Pathology have teamed up to bring molecular case reports to CAP TODAY readers. AMP members write the reports using clinical cases from their own practices that show molecular testing’s important role in diagnosis, prognosis, and treatment. This month's report comes from Aga Khan University in Karachi, Pakistan. Case. An 87-year-old male with a clinical history of hypertension and sick sinus syndrome presented with a one-month history of fever, generalized weakness, and weight loss. There was no lymphadenopathy or hepatosplenomegaly on physical examination. Bone marrow examination was performed to evaluate for cytopenias.
Read More » -
AMP case report: Potential von Hippel-Lindau syndrome in a patient with negative germline testing
-
AMP case report: Identification of multiple germline cancer predisposing gene variants in a single patient during tumor sequencing analysis
-
AMP case report: Lung micropapillary adenocarcinomas revisited
-
AMP case report: Small intragenic structural variants in SATB2-associated syndrome
MARCH 2024
-
Game’s afoot in bladder cancer research
March 2024—Like identifying the shift in battle that leads to victory, or the battle that wins the war—let alone declaring a war’s ultimate victor—it’s hard to gauge the whens, ifs, and hows that mark progress in medicine. For those who are deeply rooted in bringing advances to testing in urothelial cancers, current research is flourishing and flummoxing. In early and late stage, both for bladder and upper tract disease, recently approved therapies are leading to better outcomes for patients. More immunotherapies and antibody-drug conjugates are on their way, and with them come new options for testing. But as with any cancer, researchers follow numerous promising paths, knowing that some will dead-end and others will succeed primarily (albeit usefully) in raising more questions. Nevertheless, they continue to rally the work forward, with multiple breaches, and Agincourt, ever in sight. For experts such as David McConkey, PhD, progress will best be measured by how regularly precision makes its way into the clinical setting.
Read More » -
From training to first jobs, can the transition be made easier?
March 2024—Pathology trainees and training programs vary, as do first jobs, but the first year in pathology practice is generally said to be a tough one, largely because of the transition to fully independent case sign-out.
-
In diabetes patients, biomarker use for early-stage HF
March 2024—For patients with type 2 diabetes, the cardiac biomarkers are a better predictor of early-stage heart failure than conventional risk prediction scores. “We need to use biomarkers,” says Petr Jarolim, MD, PhD.
-
Survey probes staff shortage in genomics labs
March 2024—From a technologist workforce perspective, clinical genomics laboratories are in trouble. “It’s truly a crisis,” said Marco Leung, PhD, clinical director of the Steve and Cindy Rasmussen Institute for Genomic Medicine at Nationwide Children’s Hospital in Columbus, Ohio.
Image Credits: [do_widget id=enhancedtextwidget-12].
Video Spotlight
-
Epredia Announces Launch of SlideMate Laser
SlideMate Laser is the latest addition to Epredia’s world-class portfolio of precision cancer diagnostics products and services that provide a seamless end-to-end laboratory workflow. SlideMate Laser can integrate into a range a workflows.
Learn more. Read More »
CAP TODAY Roundtables
-
AP and CP reporting, from interfaces to IT wishes
March 2024—Anatomic and clinical pathology reporting—what’s working, what’s missing. Three pathologists (all board certified in informatics) and representatives of three information system companies met online Dec. 19 with CAP TODAY publisher Bob McGonnagle to talk about reporting needs and what’s optimal. The first half of their discussion was published in the February issue, with CAP TODAY’s guide to anatomic pathology computer systems. The second half begins here.
Read More » -
With pipeline for pathologists, others lacking, eyes on AI
-
AP and CP reporting—the needs, the caveats
-
Panelists on viscoelastic and other coag assays
CAP TODAY WEBINARS
-
Combining Clinical Signs and Symptoms with Histopathology for Definitive Diagnosis of Idiopathic Multicentric Castleman Disease (iMCD)
Webinar presenter Jade Neff, MD, PhD, Assistant Professor of Pathology, Duke University Medical Center, discusses Definitive Diagnosis of Idiopathic Multicentric Castleman Disease (iMCD), including the pivotal role that pathologists play in diagnosing iMCD, an elusive and debilitating disease that poses unique diagnostic challenges. Read More » -
Empowering Pathology Partnerships
for Growth & Rewards with GoPathWebinar presenters Jim Lu, MD, PhD, CEO, Medical Director GoPath Diagnostics, and Kenneth Bloom, MD, Head of Pathology, Nucleai, discuss the future of partnerships between community-based pathology groups and (national) laboratories, including sub-specialty coverage, workload balancing, solutions in high-tech diagnostics, turnkey support for digital path and AI, and opportunities for more revenue and higher profits.
Image Credits: [do_widget id=enhancedtextwidget-12].
REGISTER NOW
-
Register for our upcoming webinar
Liquid Biopsy and Concurrent Testing Strategies for Patients with Metastatic NSCLC
Read More »
Thursday, April 11, 2024, 12:00 PM–1:00 PM ET
Webinar presenter Zin Htway, PhD Supervisor and Operations Manager, Anatomic Pathology as HCA, Los Robles Hospital and Medical Center, will discuss the impact of liquid biopsy and concurrent biomarker testing for the appropriate care of patients with NSCLC. Dr. Htway will review the potential benefits of integrating liquid biopsy with standard-of-care tissue testing on turnaround time and identification of patients with actionable biomarkers in metastatic NSCLC and explore patient case scenarios that demonstrate potential successes and implementation considerations for concurrent liquid biopsy integration in metastatic NSCLC. -
Register for our upcoming webinar
Virtual Roundtable: Optimizing Testing for the Diagnosis of Systemic Mastocytosis
June 25, 2024, 1:00 PM–2:00 PM ET
Webinar presenters Robyn Scherber, MD, MPH Hematologist UT Health SA, Medical Director Blueprint Medicines; Anton Rets, MD, PhD Associate Professor University of Utah, Medical Director Hematopathology and Immunohistochemistry; Nathan A. Boggs, MD, PhD Assistant Professor of Medicine, Uniformed Services University Allergy Division Director will discuss the barriers and possible solutions to screening for and diagnosing Systemic Mastocytosis (SM) and recommendations that will empower cross-functional laboratory stakeholders to implement changes that can help improve the diagnosis of SM.
Image Credits: [do_widget id=enhancedtextwidget-12].
AMP Case Reports
-
AMP case report: Acute myeloid leukemia with hyperdiploidy
March 2024—CAP TODAY and the Association for Molecular Pathology have teamed up to bring molecular case reports to CAP TODAY readers. AMP members write the reports using clinical cases from their own practices that show molecular testing’s important role in diagnosis, prognosis, and treatment. This month's report comes from Aga Khan University in Karachi, Pakistan. Case. An 87-year-old male with a clinical history of hypertension and sick sinus syndrome presented with a one-month history of fever, generalized weakness, and weight loss. There was no lymphadenopathy or hepatosplenomegaly on physical examination. Bone marrow examination was performed to evaluate for cytopenias.
Read More » -
AMP case report: Potential von Hippel-Lindau syndrome in a patient with negative germline testing
-
AMP case report: Identification of multiple germline cancer predisposing gene variants in a single patient during tumor sequencing analysis
-
AMP case report: Lung micropapillary adenocarcinomas revisited
-
AMP case report: Small intragenic structural variants in SATB2-associated syndrome